A Phase 1/2 interventional study of Pexastimogene Devacirepvec (Pexa-Vec) and Cemiplimab in Renal Cell Carcinoma, sponsored by SillaJen, Inc.. Completed at 21 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by SillaJen, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Carcinoma, Renal Cell with a site in Korea, Republic of — 19 open to participants now, 39 under way, 13 of them phase 3. Carcinoma, Renal Cell · Korea, Republic of.
Among the 108 studies in Carcinoma, Renal Cell with a site in Korea, Republic of, this one is the 72nd largest by enrollment of the 93 interventional ones that give a count, is one of 4 that started in 2018, is one of 19 in phase 1/2, and was the 57th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →19 of the 108 studies in Carcinoma, Renal Cell with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Korea, Republic of, United States, Argentina and 16 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of, United States, Argentina and 17 more countries
Ages 18+
Yonsei University · Sites in Korea, Republic of
Ages 19+
Merck Sharp & Dohme LLC · Sites in Korea, Republic of, United States, Argentina and 21 more countries
Ages 18+
AstraZeneca · Sites in Korea, Republic of, United States, Australia and 1 more country
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 41 · Phase 3 29
First in 1997; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 95 is above the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 223 across the 93 interventional studies, 290 across the 14 observational. Of the 61 that completed or were terminated, 33 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 108 have an industry lead sponsor. The 10 most frequent:
SillaJen, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
SillaJen, Inc. has 1 study filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
8 of the studies in Carcinoma, Renal Cell with a site in Korea, Republic of that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05678673Phase 3ExelixisStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | 2026-12-15 |
| NCT03592472Phase 3Xynomic Pharmaceuticals, Inc.A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | 2026-12-30 |
| NCT07000149AstraZenecaA Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC | 2027-01-29 |
| NCT07172802GI Innovation, Inc.A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | 2027-02 |
Add all 8 to your calendar (.ics) → With an account.
Among the 108 studies in Carcinoma, Renal Cell with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1b/2a, open-label, multi-center, dose-escalation and safety/efficacy evaluation trial of Pexa-Vec plus Cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with Cemiplimab will be determined, followed by an expansion stage. During the expansion patients will receive Cemiplimab alone or in combination with Pexa-Vec, which will be administered either through intravenous (IV) or intratumoral (IT) injection.
For Pexa-Vec IV infusions (Part 1 / Part 2: Arm C and Arm D): Day -7, 1, 8, and 15), patients allocated to Part 1 or Part 2: Arm C or Arm D will receive an IV infusion of Pexa-Vec in approximately 250 mL buffered saline.
For Pexa-Vec IT Injections (Part 2 Arm A + Arm B), patients in Part 2, Arm A (and those in Arm B who progress on Cemiplimab monotherapy) will receive an IT injection of Pexa-Vec in a volume of buffered saline dependent on size of tumor(s).
For administration of Cemiplimab, Cemiplimab will be administered at a dose of 350 mg IV infusion over 30 minutes (±10 minutes) every 3 weeks per manufactures guidelines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 2 Arm D ONLY: Patients must be to anti or anti-PD-L1 (either as monotherapy or in-combination with other approved checkpoint inhibitors or targeted therapies according to their approved label) and patients must meet all of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pexa-Vec will be administered via IV infusion at a dose of 3 x 10\^8 pfu once per week for 4 treatments. Based on the occurrence of dose-limiting toxicities, patients may subsequently be enrolled to receive Pexa-Vec on the same schedule at a dose of 3 x 10\^8 pfu. Cemiplimab will be administered via IV infusion every 3 weeks.
Biological: Pexastimogene Devacirepvec (Pexa-Vec) · Biological: Cemiplimab
Pexa-Vec will be administered via IV infusion at a dose of 1 x 10\^9 pfu once per week for 4 treatments. Based on the occurrence of dose-limiting toxicities, patients may subsequently be enrolled to receive Pexa-Vec on the same schedule at a dose of 1 x 10\^9 pfu.
Biological: Pexastimogene Devacirepvec (Pexa-Vec) · Biological: Cemiplimab
Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments. Cemiplimab will be administered via IV infusion every 3 weeks. Pexastimogene Devacirepvec (Pexa-Vec): Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells Cemiplimab: Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
Biological: Pexastimogene Devacirepvec (Pexa-Vec) · Biological: Cemiplimab
Cemiplimab will be administered via IV infusion every 3 weeks. At disease progression, Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments. Cemiplimab will continue every 3 weeks. Pexastimogene Devacirepvec (Pexa-Vec): Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells Cemiplimab: Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
Biological: Pexastimogene Devacirepvec (Pexa-Vec) · Biological: Cemiplimab
Pexa-Vec will be administered via IV infusion once per week for 4 treatments. Cemiplimab will be administered via IV infusion every 3 weeks. Pexastimogene Devacirepvec (Pexa-Vec): Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells Cemiplimab: Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
Biological: Pexastimogene Devacirepvec (Pexa-Vec) · Biological: Cemiplimab
Pexa-Vec will be administered via IV infusion once per week for 4 treatments. Cemiplimab will be administered via IV infusion every 3 weeks. Pexastimogene Devacirepvec (Pexa-Vec): Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells Cemiplimab: Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
Biological: Pexastimogene Devacirepvec (Pexa-Vec) · Biological: Cemiplimab
Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells
Also known as: JX-594
Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
Number and Percentage of Participants With Adverse Events From Pexa-Vec Administered by IV Infusions or IT Injections in Combination With IV Cemiplimab
Safety will be determined by assessing the incidence, severity, and frequency of all treatment-emergent adverse events (TEAEs), Grade 3 or greater AEs, serious adverse events (SAEs), laboratory toxicity, AEs requiring discontinuation of study agent(s), and deaths. The severity of all adverse events and laboratory abnormalities is assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. Safety is monitored from the first dose throughout the treatment period (up to a maximum of 1 year) and up to 28 days after the last dose of study treatment.
Time frame: Through study completion without survival follow-up period, an average of 1 year
Overall Response Rate
Overall response rate (ORR) is defined as the proportion of patients whose best overall responses either complete response (CR) or partial response (PR). The best overall response is the best response recorded from the randomization until disease progression. Proportions of patients with a best overall response of CR, disappearance of all target tumors; or PR, at least 30% decrease in the sum of longest diameter of target tumors will be presented by treatment arm along with exact 95% CIs. Analyses will be performed based on central assessments using RECIST v1.1.
Time frame: Every 9 weeks until documented progression or discontinuation beyond documented progression. After 1 year, every 12 weeks from EOT visit, up to 36 months.
Number of Participants With Dose Limiting Toxicities of Pexa-Vec Administered by IV Infusions in Combination With Cemiplimab (Part 1 Only)
Dose-limiting toxicity (DLT) was assessed to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of Pexa-Vec. Patients were observed for DLTs during the IV treatment phase through Day 29. DLTs are evaluated based on the severity and frequency of adverse events and laboratory abnormalities using NCI CTCAE Version 5.0.
Time frame: The 29-day cycle of therapy
Progression Free Survival
Defined as the date of the first study treatment to the date of first documented radiographic tumor progression or death due to any cause, whichever occurs first (RECIST v1.1). Progression free survival will be presented descriptively using Kaplan-Meier curves. Summary statistics from the Kaplan-Meier distributions will be determined, including median PFS and 25% and 75% quartiles with corresponding 95% CIs. The proportions of patients.
Time frame: Every 9 weeks until documented progression or discontinuation beyond documented progression. After 1 year, every 12 weeks from EOT visit, up to 36 months
Disease Control Rate
Defined as the proportion of patients whose best overall response is either complete response (CR), partial response (PR), or stable disease (SD). (RECIST v1.1)
Time frame: Every 9 weeks until documented progression or discontinuation beyond documented progression. After 1 year, every 12 weeks from EOT visit, up to 36 months
Overall Survival
Overall survival is defined as the time from first study treatment until death from any cause. For patients not known to have died at the time of the analysis, overall survival will be censored on the date they were last known to be alive. If a patient withdraws early, overall survival will not be censored at the date of withdrawal unless this is the date they were last known to be alive. Date of death will be obtained from the death certificate (preferable) or from a written statement from the primary care or attending physician, or from death registry data. Additionally, for censored date, the latest date of (in the following order): End of Treatment visit(EOT) / Last Radiologic Timepoint(LastRTP) / End of Study(EOS) / Last Drug Date(D.LastDrug) / before cutoff date(2023-02-16) is the censored date.
Time frame: Every 9 weeks until documented progression or discontinuation beyond documented progression. After 1 year, every 12 weeks from EOT visit, up to 36 months
Patients with histologically or cytologically confirmed metastatic or unresectable clear cell Renal Cell Carcinoma (RCC) were recruited for this study. The recruitment took place at 17 study centers across the United States, South Korea, and Australia. The first patient was enrolled on June 19, 2018, and the last patient completed the study on February 16, 2023. It was noted that there were some recruitment limitations due to intratumoral injection constraints.
| Milestone | Part 1 3 x 10^8 Pfu | Part 1 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 15 | 16 | 30 | 28 |
| Completed | 0 | 0 | 6 | 5 | 8 | 6 |
| Not completed | 3 | 3 | 9 | 11 | 22 | 22 |
Safety will be determined by assessing the incidence, severity, and frequency of all treatment-emergent adverse events (TEAEs), Grade 3 or greater AEs, serious adverse events (SAEs), laboratory toxicity, AEs requiring discontinuation of study agent(s), and deaths. The severity of all adverse events and laboratory abnormalities is assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. Safety is monitored from the first dose throughout the treatment period (up to a maximum of 1 year) and up to 28 days after the last dose of study treatment.
| Participants | Part 1 3 x 10^8 Pfu | Part 1 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab |
|---|---|---|---|---|---|---|
| Grade 3 or greater AEs | 1 | 2 | 8 | 7 | 12 | 13 |
| Serious adverse events | 2 | 1 | 6 | 6 | 11 | 11 |
| AEs requiring discontinuation of study agent(s) | 0 | 0 | 3 | 1 | 2 | 2 |
| Deaths according to NCI-CTC V5 | 0 | 0 | 0 | 0 | 0 | 0 |
Overall response rate (ORR) is defined as the proportion of patients whose best overall responses either complete response (CR) or partial response (PR). The best overall response is the best response recorded from the randomization until disease progression. Proportions of patients with a best overall response of CR, disappearance of all target tumors; or PR, at least 30% decrease in the sum of longest diameter of target tumors will be presented by treatment arm along with exact 95% CIs. Analyses will be performed based on central assessments using RECIST v1.1.
| percentage of participants | Part 1 3 x 10^8 Pfu | Part 1 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab |
|---|---|---|---|---|---|---|
| Overall Response Rate | 33.3 (NA to NA) | 33.3 (NA to NA) | 13.3 (1.7 to 40.5) | 12.5 (1.6 to 38.3) | 23.3 (9.9 to 42.3) | 17.9 (6.06 to 36.9) |
Dose-limiting toxicity (DLT) was assessed to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of Pexa-Vec. Patients were observed for DLTs during the IV treatment phase through Day 29. DLTs are evaluated based on the severity and frequency of adverse events and laboratory abnormalities using NCI CTCAE Version 5.0.
| participants | Part 1: 3 x 10^8 Pfu | Part 1: 1 x 10^9 Pfu |
|---|---|---|
| Number of Participants With Dose Limiting Toxicities of Pexa-Vec Administered by IV Infusions in Combination With Cemiplimab (Part 1 Only) | 0 | 0 |
Defined as the date of the first study treatment to the date of first documented radiographic tumor progression or death due to any cause, whichever occurs first (RECIST v1.1). Progression free survival will be presented descriptively using Kaplan-Meier curves. Summary statistics from the Kaplan-Meier distributions will be determined, including median PFS and 25% and 75% quartiles with corresponding 95% CIs. The proportions of patients.
| Months | Part 1 3 x 10^8 Pfu | Part 1 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab |
|---|---|---|---|---|---|---|
| Progression Free Survival | NA (NA to NA) | NA (NA to NA) | 4.27 (2.37 to NA) | 5.65 (2.07 to NA) | 4.57 (4.34 to 15.44) | 6.31 (3.29 to NA) |
Defined as the proportion of patients whose best overall response is either complete response (CR), partial response (PR), or stable disease (SD). (RECIST v1.1)
| percentage of participants | Part 1 3 x 10^8 Pfu | Part 1 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab |
|---|---|---|---|---|---|---|
| Disease Control Rate | 66.6 (NA to NA) | 33.3 (NA to NA) | 60.0 (32.3 to 83.7) | 56.3 (29.9 to 80.2) | 63.3 (43.9 to 80.1) | 67.9 (47.6 to 84.1) |
Overall survival is defined as the time from first study treatment until death from any cause. For patients not known to have died at the time of the analysis, overall survival will be censored on the date they were last known to be alive. If a patient withdraws early, overall survival will not be censored at the date of withdrawal unless this is the date they were last known to be alive. Date of death will be obtained from the death certificate (preferable) or from a written statement from the primary care or attending physician, or from death registry data. Additionally, for censored date, the latest date of (in the following order): End of Treatment visit(EOT) / Last Radiologic Timepoint(LastRTP) / End of Study(EOS) / Last Drug Date(D.LastDrug) / before cutoff date(2023-02-16) is the censored date.
| month | Part 1 3 x 10^8 Pfu | Part 1 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab |
|---|---|---|---|---|---|---|
| Overall Survival | NA (NA to NA) | NA (NA to NA) | 21.98 (21.98 to NA) | 20.83 (19.52 to NA) | 25.13 (22.01 to NA) | 18.53 (14.75 to NA) |
Collected over All-Cause Mortality was assessed throughstudy completion, up to 36 months; all adverse events were collected through studycompletion with survival follow-up period, an average of 1 year". Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 3 x 10^8 Pfu | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 1 1 x 10^9 Pfu | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | 3/15 (20%) | 6/15 (40%) | 15/15 (100%) |
| Part 2-Arm B, Cemiplimab | 2/16 (12.5%) | 6/15 (40%) | 15/15 (100%) |
| Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | 5/30 (16.7%) | 11/30 (36.7%) | 30/30 (100%) |
| Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab | 5/28 (17.9%) | 11/28 (39.3%) | 28/28 (100%) |
| Event | Part 1 3 x 10^8 Pfu | Part 1 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab |
|---|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 1/3 | 0/3 | 0/15 | 0/15 | 0/30 | 0/28 |
| SepsisInfections and infestations | 0/3 | 1/3 | 0/15 | 0/15 | 0/30 | 0/28 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/3 | 0/3 | 0/15 | 0/15 | 0/30 | 0/28 |
| Spinal cord compressionNervous system disorders | 0/3 | 0/3 | 0/15 | 2/15 | 1/30 | 0/28 |
| HaematuriaRenal and urinary disorders | 0/3 | 0/3 | 1/15 | 0/15 | 0/30 | 2/28 |
| Histiocytosis haematophagicBlood and lymphatic system disorders | 0/3 | 0/3 | 0/15 | 1/15 | 0/30 | 0/28 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/3 | 0/3 | 0/15 | 1/15 | 0/30 | 0/28 |
| PneumoniaInfections and infestations | 0/3 | 0/3 | 1/15 | 0/15 | 1/30 | 1/28 |
| Pulmonary tuberculosisInfections and infestations | 0/3 | 0/3 | 1/15 | 0/15 | 0/30 | 0/28 |
| PyrexiaGeneral disorders | 0/3 | 0/3 | 1/15 | 0/15 | 1/30 | 1/28 |
| Event | Part 1 3 x 10^8 Pfu | Part 1 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab |
|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 3/3 | 3/3 | 15/15 | 9/15 | 30/30 | 25/28 |
| ChillsGeneral disorders | 1/3 | 2/3 | 2/15 | 2/15 | 9/30 | 10/28 |
| Rash pustularInfections and infestations | 2/3 | 1/3 | 2/15 | 1/15 | 9/30 | 7/28 |
| HypotensionVascular disorders | 0/3 | 2/3 | 2/15 | 1/15 | 5/30 | 9/28 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 0/3 | 0/15 | 4/15 | 5/30 | 7/28 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/3 | 2/3 | 2/15 | 0/15 | 4/30 | 2/28 |
| RashSkin and subcutaneous tissue disorders | 0/3 | 2/3 | 0/15 | 2/15 | 4/30 | 2/28 |
| NauseaGastrointestinal disorders | 1/3 | 1/3 | 1/15 | 5/15 | 4/30 | 10/28 |
| FatigueGeneral disorders | 1/3 | 0/3 | 2/15 | 1/15 | 4/30 | 10/28 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 1/3 | 4/15 | 1/15 | 2/30 | 7/28 |
| Age, Categorical(Participants) | Part 1 : 3 x 10^8 Pfu | Part 1 : 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 3 | 13 | 9 | 20 | 20 | 66 |
| >=65 years | 2 | 0 | 2 | 7 | 10 | 8 | 29 |
| Age, Continuous(years) | Part 1 : 3 x 10^8 Pfu | Part 1 : 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab | Total |
|---|---|---|---|---|---|---|---|
| Mean | 59.7 ± 14.43 | 54.3 ± 7.77 | 58.4 ± 7.81 | 61.0 ± 10.03 | 60.1 ± 9.63 | 61.3 ± 6.81 | 60.3 ± 8.53 |
| Sex: Female, Male(Participants) | Part 1 : 3 x 10^8 Pfu | Part 1 : 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 5 | 5 | 6 | 6 | 24 |
| Male | 2 | 2 | 10 | 11 | 24 | 22 | 71 |
| Race (NIH/OMB)(Participants) | Part 1 : 3 x 10^8 Pfu | Part 1 : 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 14 | 16 | 25 | 12 | 71 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 1 | 1 | 1 | 0 | 4 | 15 | 22 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 : 3 x 10^8 Pfu | Part 1 : 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 0 | 6 | 7 |
| Not Hispanic or Latino | 3 | 3 | 14 | 16 | 30 | 22 | 88 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part 1 : 3 x 10^8 Pfu | Part 1 : 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab | Total |
|---|---|---|---|---|---|---|---|
| United States | 1 | 1 | 1 | 0 | 3 | 15 | 21 |
| South Korea | 2 | 2 | 14 | 16 | 25 | 12 | 71 |
| Australia | 0 | 0 | 0 | 0 | 2 | 1 | 3 |
| Baseline Tumor Size(Centimeters (cm)) | Part 1 : 3 x 10^8 Pfu | Part 1 : 1 x 10^9 Pfu | Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab | Part 2-Arm B, Cemiplimab | Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab | Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab | Total |
|---|---|---|---|---|---|---|---|
| Mean | 6.175 ± 0.5020 | 13.953 ± 7.0135 | 20.030 ± 8.8899 | 17.808 ± 10.7614 | 9.642 ± 6.3913 | 11.320 ± 9.3731 | 13.03 ± 9.26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2018 to primary completion in Feb 2023, 55 months.
Results were first posted in Jun 2026, 3 years 4 months after primary completion.
Of 70 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's 55 months is below that.
Counting every sponsor, half of 111 studies reached it within 64 months; a quarter within 45 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: JX-594 · Cemiplimab
SillaJen, Inc.